Prophylactic Ivermectin in COVID-19 Contacts
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04422561 |
Recruitment Status :
Completed
First Posted : June 9, 2020
Results First Posted : August 27, 2020
Last Update Posted : August 27, 2020
|
Sponsor:
Zagazig University
Information provided by (Responsible Party):
Waheed Shouman, Zagazig University
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Study Type | Interventional |
---|---|
Study Design | Allocation: Randomized; Intervention Model: Sequential Assignment; Masking: None (Open Label); Primary Purpose: Prevention |
Condition |
COVID |
Intervention |
Drug: Ivermectin Tablets |
Enrollment | 340 |
Participant Flow
Recruitment Details | |
Pre-assignment Details |
Arm/Group Title | Ivermectin Group | Control Group |
---|---|---|
![]() |
Contacts who will receive prophylactic ivermectin Ivermectin Tablets: 40-60 kg (15mg/day) 60-80kg (18mg/day) >80kg (24mg/day) |
Contacts who will be only observed without prophylaxis |
Period Title: Overall Study | ||
Started | 228 | 112 |
Completed | 203 | 101 |
Not Completed | 25 | 11 |
Reason Not Completed | ||
Lost to Follow-up | 25 | 11 |
Baseline Characteristics
Arm/Group Title | Ivermectin Group | Control Group | Total | |
---|---|---|---|---|
![]() |
Contacts who will receive prophylactic ivermectin Ivermectin Tablets: 40-60 kg (15mg/day) 60-80kg (18mg/day) >80kg (24mg/day) |
Contacts who will be only observed without prophylaxis | Total of all reporting groups | |
Overall Number of Baseline Participants | 203 | 101 | 304 | |
![]() |
[Not Specified]
|
|||
Age, Continuous
Mean (Standard Deviation) Unit of measure: Years |
||||
Number Analyzed | 203 participants | 101 participants | 304 participants | |
39.75 (14.93) | 37.69 (16.95) | 38.72 (15.94) | ||
Sex: Female, Male
Measure Type: Count of Participants Unit of measure: Participants |
||||
Number Analyzed | 203 participants | 101 participants | 304 participants | |
Female |
97 47.8%
|
51 50.5%
|
148 48.7%
|
|
Male |
106 52.2%
|
50 49.5%
|
156 51.3%
|
|
Race and Ethnicity Not Collected
[1] Measure Type: Count of Participants Unit of measure: Participants |
||||
Number Analyzed | 0 participants | 0 participants | 0 participants | |
0 | ||||
[1]
Measure Analysis Population Description: Race and Ethnicity were not collected from any participant.
|
Outcome Measures
Adverse Events
Limitations and Caveats
[Not Specified]
More Information
Results Point of Contact
Name/Title: | Dr. Waheed Shouman |
Organization: | Zagazig University |
Phone: | +201114812048 |
EMail: | shouman66@gmail.com |
Responsible Party: | Waheed Shouman, Zagazig University |
ClinicalTrials.gov Identifier: | NCT04422561 |
Other Study ID Numbers: |
ZU-IRB#6150/31-5-2020 |
First Submitted: | June 6, 2020 |
First Posted: | June 9, 2020 |
Results First Submitted: | August 23, 2020 |
Results First Posted: | August 27, 2020 |
Last Update Posted: | August 27, 2020 |